GlassScriptPhysician profile
Neil R Katz
NPI 1669414892
$4,190.31
in general payments reported to CMS, 2019-2025
31 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $449 · 2021: $249 · 2022: $329 · 2023: $357 · 2024: $774 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,568.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $767.22 | 2022-2025 | Rocklatan, Rhopressa, Tryptyr |
| Abbvie INC. | $501.80 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $380.46 | 2019-2025 | |
| Kala Pharmaceuticals, INC. | $345.55 | 2019-2022 | |
| Rxsight INC | $322.62 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Novartis Pharmaceuticals Corporation | $294.78 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $209.00 | 2023-2025 | Miebo, Envista Mx60 Iol |
| Tarsus Pharmaceuticals, INC. | $158.06 | 2024-2025 | Xdemvy |
| Amgen INC. | $131.91 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $125.74 | 2019-2020 | |
| Astellas Pharma US INC | $111.18 | 2023-2025 | Izervay |
| Harrow Eye, LLC | $87.90 | 2024-2025 | Vevye |
| Allergan, INC. | $81.71 | 2019-2021 | |
| Alimera Sciences, INC. | $70.15 | 2020-2023 | Yutiq |
| Sight Sciences, INC. | $69.21 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $68.78 | 2019-2021 | |
| Oyster Point Pharma, INC. | $68.71 | 2022-2025 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $66.74 | 2025 | Acthar |
| Horizon Therapeutics Plc | $65.65 | 2022-2023 | Tepezza |
| Genzyme Corporation | $41.20 | 2019 | |
| Rayner Intraocular Lenses Limited | $36.31 | 2025 | Rayner Cataract Set 1, Rayone Aspheric, Rayone Spheric |
| Dompe US, INC. | $28.56 | 2025 | Oxervate |
| Ani Pharmaceuticals, INC. | $24.91 | 2025 | Purified Cortrophin Gel |
| Eyevance Pharmaceuticals LLC | $24.61 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.92 | 2019 | |
| Visioneering Technologies, INC. | $17.75 | 2019 | |
| Ocular Therapeutix, INC. | $15.76 | 2024 | Dextenza |
| Eyepoint US, INC. | $15.68 | 2019 | |
| Vyera Pharmaceuticals, LLC | $11.99 | 2020 | |
| Alcon Research LLC | $11.77 | 2019 | |
| Spark Therapeutics, INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.